Neola Medical AB (SE:NEOLA)
:NEOLA
Want to see SE:NEOLA full AI Analyst Report?
NEOLA Stock Chart & Stats
kr1.08
kr0.08(3.31%)
At close: 4:00 PM EST
kr1.08
kr0.08(3.31%)
Day’s Range― - ―
52-Week Rangekr0.60 - kr3.04
Previous CloseN/A
Volume18.12K
Average Volume (3M)12.79K
Market Cap
kr93.54M
Enterprise Valuekr77.42M
Total Cash (Recent Filing)kr22.12M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding77,950,230
10 Day Avg. Volume10,323
30 Day Avg. Volume12,794
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.07
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr9.10M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt and roughly SEK 75.8M in equity give the company a low-leverage balance sheet. This reduces near-term solvency risk, extends runway for R&D and clinical validation, and provides strategic flexibility while commercialization efforts continue.
Product / Structural Market FitNeola’s core product is a non-invasive sensor system for vital-sign monitoring. Structural healthcare trends favor non-invasive, continuous monitoring to reduce complications and costs in clinical settings, supporting durable product-market fit and adoption potential.
Controlled Cash BurnOperating and free cash flow remain negative, but management has kept cash burn relatively steady versus prior years. Predictable, controlled cash consumption preserves runway and allows focused execution on clinical validation and commercialization planning.
Bears Say
No Meaningful RevenueReported revenue has been effectively zero for multiple years, indicating the product has not yet generated market sales at scale. Persistent lack of revenue raises uncertainty around commercialization success and long-term viability without external funding.
Persistent Net LossesThe company recorded an approximate SEK 11.0M net loss in 2025 with recurring negative EBIT/EBITDA. Ongoing losses erode equity over time, increase probability of future capital raises, and can limit resources available for scaling sales, regulatory work, and product development.
Negative Operating Cash FlowOperating cash flow remains negative and free cash flow has been negative most years, meaning core operations do not self-fund. This dependence on external financing increases vulnerability to capital market conditions and may force dilution or cost-cutting if revenues don't ramp.
Neola Medical AB News
NEOLA FAQ
What was Neola Medical AB’s price range in the past 12 months?
Neola Medical AB lowest stock price was kr0.60 and its highest was kr3.04 in the past 12 months.
What is Neola Medical AB’s market cap?
Neola Medical AB’s market cap is kr93.54M.
When is Neola Medical AB’s upcoming earnings report date?
Neola Medical AB’s upcoming earnings report date is May 27, 2026 which is in 23 days.
How were Neola Medical AB’s earnings last quarter?
Neola Medical AB released its earnings results on Feb 12, 2026. The company reported -kr0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.034.
Is Neola Medical AB overvalued?
According to Wall Street analysts Neola Medical AB’s price is currently Overvalued.
Does Neola Medical AB pay dividends?
Neola Medical AB does not currently pay dividends.
What is Neola Medical AB’s EPS estimate?
Neola Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neola Medical AB have?
Neola Medical AB has 77,950,230 shares outstanding.
What happened to Neola Medical AB’s price movement after its last earnings report?
Neola Medical AB reported an EPS of -kr0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.267%.
Which hedge fund is a major shareholder of Neola Medical AB?
Currently, no hedge funds are holding shares in SE:NEOLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neola Medical AB
Neola Medical AB (publ) develops medical equipment for continuous monitoring of the lungs of premature babies. It offers neonatal intensive care with NEOLA, a medical device that offer continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. NEOLA provides intensive care and healthier lives for preterm born infants. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden.
Technical Analysis
SciBase Holding AB
―
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Nosa Plugs AB
―
Arcoma AB
―